If you have been reading about peptide research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-07. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
=== China === Gelatine dessert in China is defined as edible jelly-like food prepared from a mixture of water, sugar and gelling agent. The preparation processes include concocting, gelling, sterilising and packaging. In China, around 250 legal additives are allowed in gelatine desserts as gelling agents, colours, artificial sweeteners, emulsifiers and antioxidants. Gelatine desserts are classified into 5 categories according to the different flavouring substances they contain. Five types of flavouring substance include artificial fruit flavoured type (less than 15% of natural fruit juice), natural fruit flavoured type (above 15% of natural fruit juice), natural flavoured with fruit pulp type and dairy type products, which includes dairy ingredients. The last type ("others") summarises gelatine desserts not mentioned above. It is typically sold in single-serving plastic cups or plastic food bags.
Food and Drug Administration (FDA) also assigned it to a Schedule I classification, and the International Olympic Committee banned it as a potential doping agent. Anecdotal reports concerning ibogaine's effects appeared in the early 1960s. Its anti-addictive properties were discovered accidentally by Howard Lotsof in 1962, at the age of 19, when he and five friends—all heroin addicts—noted subjective reduction of their craving and withdrawal symptoms while taking it. Further anecdotal observation convinced Lotsof of its potential usefulness in treating substance addictions. He contracted with a Belgian company to produce ibogaine in tablet form with the name Endabuse for clinical trials in the Netherlands, and was awarded a United States patent for the product in 1985. The first objective, placebo-controlled evidence of ibogaine's ability to attenuate opioid withdrawal in rats, was published by Dzoljic et al. in 1988. Diminution of morphine self-administration was reported in preclinical studies by Glick et al. in 1991. Cappendijk et al. demonstrated reduction in cocaine self-administration in rats in 1993, and Rezvani reported reduced alcohol dependence in three strains of "alcohol-preferring" rats in 1995. As the use of ibogaine spread, its administration varied widely; some groups administered it systematically using well-developed methods and medical personnel, while others employed haphazard and possibly dangerous methodology. Lotsof and his colleagues, committed to the traditional administration of ibogaine, developed treatment regimens themselves.
=== Clean energy roll-back === The bill was described by The New York Times as derailing renewable energy production and research in the United States, and possibly ceding the clean energy race to China. Its policies favor fossil fuel companies over renewable energy such as solar, wind, and EV manufacturing, and are expected to lead to large clean energy job losses, factory closures, and deter investment in clean technologies. Specifically, the law phases out most clean-energy tax incentives introduced under the Biden-era Inflation Reduction Act such as credits for low-carbon electricity (wind, solar), electric vehicle rebates, home electrification, clean hydrogen, and domestic manufacturing of batteries and solar panels. The law rescinds various IRA funds for grants related to freeway removal improving biking and walking in poorer neighborhoods, electric truck and bus manufacturing, faster state and local environmental reviews and place-based green industrial policy and home electrification. An April 2026 study projected the IRA's impact on clean energy investments would be nearly wiped out by the OBBBA, and emissions would be reduced by only 34 percent below 2005 levels, compared to 44 percent with the IRA. A report released by environmental group BlueGreen Alliance found that the OBBBA caused 223 manufacturing and clean energy projects to stall or be cancelled, affecting over 111,000 jobs and $82.9 billion in investment.
==== Effects on mental health ==== Based on a nationally representative sample of 20,847 US adults, a 2026 survey study in JAMA Network Open found that daily generative AI use was significantly associated with greater depressive symptoms, with the odds of at least moderate depression roughly 30% higher among daily users than among non-users. The association was strongest for personal use and among those aged 25 to 64; the cross-sectional design did not allow for causal conclusions. Separately, a 2025 nationally representative survey of US adolescents and young adults (aged 12 to 21) found that roughly 13% had used generative AI for emotional support, with more than 90% of them reporting the advice as helpful. Controlled trials have shown some therapeutic potential. The first randomized controlled trial of a fully generative AI therapy chatbot, published in NEJM AI in 2025, found significant reductions in symptoms of depression, anxiety, and eating disorders over four weeks compared to a waitlist control, with participants rating the therapeutic alliance as comparable to that of human therapists. These findings are consistent with a 2025 meta-analysis of 31 RCTs (n=29,637) that found small-to-moderate effects of AI chatbots in reducing depressive, anxiety, and stress symptoms among young adults.
Sources: en.wikipedia.org
=== Human populations === Bracken fern increases the oncogenic risk in humans. Epidemiological survey revealed that bracken fern consumption was positively correlated with esophageal cancer and with gastric cancer in many geographical areas of the world. In 1989, Natori and co-workers showed that ptaquiloside had clastogenic effect and caused chromosomal aberration in mammalian cells. In 2003, Santos group reported significantly increased levels of chromosomal abnormalities, such as chromatid breaks in cultured peripheral lymphocytes.
== Miscellaneous == John Parke Custis* (1777), stepson of George Washington Philip Hamilton (1800), eldest son of Alexander Hamilton and Elizabeth Schuyler Hamilton David Augustus Clarkson (1810), landowner and grandson-in-law of Robert R. Livingston James Lenox (1818), bibliophile, founder of the Lenox Library, later incorporated into the New York Public Library; also founder of the Presbyterian Hospital John Lloyd Stephens (1822), explorer, archaeologist, special ambassador to Central America, and president of the Panama Railroad William R. Travers (1838), founder of the Travers Stakes William H. Herriman (1849), expatriate American art collector Cornelius Jeremiah Vanderbilt* (1850), son of Cornelius Vanderbilt Augustus Newbold Morris (1860), socialite and former president of The Metropolitan Club Winthrop Rutherfurd (1884), socialite known for his romance with Consuelo Vanderbilt and marriage to Lucy Mercer Rutherfurd, mistress of Franklin D. Roosevelt Gavin Arthur (1922), San Francisco astrologer and sexologist; grandson of U.S. President Chester A. Arthur Oswald Jacoby (1922), bridge player Fred Glazer (1958), librarian and director of the West Virginia Library Commission Arthur MacArthur IV (1960), son of General of the Army Douglas MacArthur Ashrita Furman (1976), holder of the most Guinness Book of World Records records Daniel Kottke (1977), college friend of Steve Jobs and 12th employee of Apple Inc. Sergey Kudrin (1981), chess grandmaster and three-time winner of the U.S.
US pathology firm CPL-Clinical Pathology Laboratories for $US123.5 million (A$121.5 million). In 2010, Sonic Healthcare acquired Labor Lademannbogen (Hamburg, Germany) and Medhold Group (Antwerp, Belgium), and through the IPN the Prime Health Group. In the US, the company acquired CBLPath (Rye Brook, NY) and Physician's Automated Laboratory (Bakersfield, California).
Sources: en.wikipedia.org
== Plunge freezing == The method involves ultra-rapid cooling of small tissue or cell samples to the temperature of liquid nitrogen (−196 °C) or below, stopping all motion and metabolic activity and preserving the internal structure by freezing all fluid phases solid. Typically, a sample is plunged into liquid nitrogen or into liquid ethane or liquid propane in a container cooled by liquid nitrogen. The ultimate objective is to freeze the specimen so rapidly (at 104 to 106 K per second) that ice crystals are unable to form, or are prevented from growing big enough to cause damage to the specimen's ultrastructure. The formation of samples containing specimens in amorphous ice is the "holy grail" of biological cryomicroscopy. In practice, it is very difficult to achieve high enough cooling rates to produce amorphous ice in specimens more than a few micrometres in thickness. For this purpose, plunging a specimen into liquid nitrogen at its boiling point (−196 °C) does not always freeze the specimen fast enough, for several reasons. First, the liquid nitrogen boils rapidly around the specimen forming a film of insulating N2 gas that slows heat transfer to the cryogenic liquid, known as the Leidenfrost effect. Cooling rates can be improved by pumping the liquid nitrogen with a rotary vane vacuum pump for a few tens of seconds before plunging the specimen into it.
The 1958 Convention on the High Seas defined "high seas" to mean "all parts of the sea that are not included in the territorial sea or in the internal waters of a State" and where "no State may validly purport to subject any part of them to its sovereignty". Ships sailing the high seas are generally under the jurisdiction of their flag state (if there is one); however, when a ship is involved in certain criminal acts, such as piracy, any nation can exercise jurisdiction under the doctrine of universal jurisdiction regardless of maritime borders. As part of their air and maritime border control policies, most countries restrict or regulate the ability of foreign airlines and vessels to transport goods or passengers between seaports and airports in their jurisdiction, known as cabotage. Restrictions on maritime cabotage exist in most countries with territorial and internal waters to protect the domestic shipping industry from foreign competition, preserve domestically owned shipping infrastructure for national security, and ensure safety in congested territorial waters. For example, in America, the Jones Act provides for extremely strict restrictions on cabotage. Similarly, China does not permit foreign flagged vessels to conduct domestic transport or domestic transhipments without the prior approval of the Ministry of Transport. While Hong Kong and Macau maintain distinct internal cabotage regimes from the mainland, maritime cabotage between either territory and the mainland is considered domestic carriage and accordingly is off limits to foreign vessels.
peptidoglycan Also murein. A glycoconjugate complex of interwoven peptides and polysaccharides that is a primary constituent of the cell wall in all bacteria and archaea, consisting of strands of glycosaminoglycans crosslinked by short oligopeptides (usually 4–10 residues) to form a rigid lattice of indefinite size. The proportion of the cell wall that is peptidoglycan varies widely by strain and is often used to aid strain identification: the higher peptidoglycan content of the cell walls of Gram-positive bacteria causes them to stain a darker color than Gram-negative bacteria.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.